<DOC>
	<DOCNO>NCT01046318</DOCNO>
	<brief_summary>The purpose clinical study evaluate safety efficacy OPC-262 5 mg patient type 2 diabetes repeat administration orally 52 week .</brief_summary>
	<brief_title>A Study OPC-262 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Type 2 diabetes patient HbA1C 6.5 % 10 % time 1st 2nd screening examination undergo diet exercise therapy least 8 week prior 1st screen examination 2 . Patients capable give informed consent 3 . Patients able take contraceptive measure avoid pregnancy patient patient 's partner entire study period 4 week study ( end postobservation period ) 1 . Patients type 1 diabetes mellitus , patient diabetes mellitus due specify drug , mechanism disease , patient gestational diabetes mellitus 2 . Patients medical history diabetic coma 3 . Patients poorlycontrolled hypertension 4 . Patients heart failure 5 . Patients complication active hepatitis hepatic cirrhosis 6 . Patients undergoing treatment glomerular disease diabetic nephropathy 7 . Patients history complication malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>